(The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Saoyuth Nidh
+41 22 414 46 77 
Merck Serono’s EPP to Finance the Launch of the EspeRare Foundation, a
Nonprofit Organization to Advance Treatments for Rare Diseases 
• Merck Serono to endow the EspeRare Foundation with a €2.8 million funding
  and the rights to a former Merck Serono compound to be actively
  in Duchenne Muscular Dystrophy, a rare pediatric disease with very
  treatment options 
Geneva, Switzerland, April 15, 2013 – Merck Serono, a division of Merck,
Darmstadt, Germany, today announced the launch of the EspeRare Foundation,
a nonprofit organization set up by three Merck Serono employees, in the
framework of the Merck Serono Entrepreneur Partnership Program (EPP). Merck
Serono will donate an initial €2.8 million funding to the EspeRare
Foundation. In addition, Merck Serono will transfer the rights of
rimeporide, a compound previously developed for heart failure by Merck. The
Foundation will investigate this compound in Duchenne Muscular Dystrophy
(DMD), a lethal genetic rare disease affecting 1 in every 3 600 males. 
The complete news release can be downloaded at the following link:$File/EspeRareEn.pdf 
News releases from Merck KGaA, Darmstadt, Germany, are available at this
address: or for residents in the USA and Canada at 
In case you are a resident of the USA or Canada please go to to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
You may change your subscription at any time by following either one of the
following links: or
And please feel free to unsubscribe this service with either or
Thank you very much! 
Merck KGaA ,Darmstadt, Germany
External Communications
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
Click to access the German, French, Spanish and
Portuguese versions of this disclaimer.
Press spacebar to pause and continue. Press esc to stop.